Mainz Biomed

Mainz Biomed is a molecular genetics cancer diagnostics company with its flagship product, ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer. ColoAlert is currently sold in Europe, with FDA clinical studies and submission processes planned to commence in the first half of 2022 for U.S. regulatory approval.